NCT05108766View on ClinicalTrials.gov

A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis

PHASE3CompletedINTERVENTIONAL

Enrollment

220

Participants

Timeline

Start Date

December 17, 2020

Primary Completion Date

June 7, 2021

Study Completion Date

July 8, 2022

Conditions

Plaque Psoriasis

Interventions

DRUG

Tildrakizumab 100 mg

Tildrakizumab 100 mg administered SC. Each PFS contains 1 mL of solution, tildrakizumab 100 mg/mL.

DRUG

Placebo

Matching placebo to tildrakizumab administered SC

Trial Locations (1)

Unknown

The First Affiliated Hospital of Air Force Medical University of PLA, Xi'an

All Listed Sponsors

lead

Shenzhen Kangzhe Pharmaceutical Co., Ltd.

INDUSTRY

NCT05108766 - A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype Psoriasis | Biotech Hunter | Biotech Hunter